RSS Feeds
Treatment of Cytomegalovirus Pneumonia with 9-[2-Hydroxy-1-(Hydroxymethyl) ethoxymethyl] Guanine and High-Dose Corticosteroids
- ELIZABETH C. REED, M.D.;
- PAULA S. DANDLIKER, M.S.N.; and
- JOEL D. MEYERS, M.D.
- Fred Hutchinson Cancer Research Center and the University of Washington School of Medicine; Seattle, Washington .
Excerpt
Effective treatment for cytomegalovirus pneumonia, a major cause of mortality in marrow transplant patients, remains elusive. A new acyclic nucleoside, 9-[2-hydroxy-1-(hydroxy methyl) ethoxy methyl] guanine (DHPG; BW B759U, Burroughs-Wellcome, Research Triangle Park, North Carolina) has been shown to have both in-vitro and in-vivo activity against cytomegalovirus but did not improve survival when used to treat cytomegalovirus pneumonia in marrow transplant recipients, although it caused a significant reduction in the amount of virus in lung tissue (1). Because the progressive pulmonary failure may have resulted from a persistent inflammatory response in the lung induced by the virus, we used DHPG combined
This 100-word excerpt has been provided in the absence of an abstract.
Acknowledgments
ACKNOWLEDGMENTS: Determination of DHPG levels was provided by Barbara Chinnock and Henry H. Balfour, Jr., M.D., University of Minnesota.
Article and Author Information
-
Grant support: by a grant from the Burroughs Wellcome Company; by grants CA 18029 and CA 15704 from the National Institutes of Health; and in part by a grant from the Poncin Scholarship Fund (Dr. Reed).
-
Reprints are not available.
